On July 26, 2019, the Board of Directors of Catabasis Pharmaceuticals, Inc. elected Hugh M. Cole as a director, effective immediately. Mr. Cole will serve as a Class II director with a term expiring at the company’s 2020 annual meeting of the stockholders of the company and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Cole has served as the Chief Business Officer and Head of Corporate Development at Jounce Therapeutics. Prior to Jounce, Mr. Cole worked at ARIAD Pharmaceuticals, where he served as Chief Business Officer from March 2014 to May 2017. Before ARIAD, he held positions of increasing responsibility at Shire plc, most recently Senior Vice President, Strategic Planning & Program Management.